Verastem raises $100M, plots path forward with targeted cancer combo

The biotech will scale back some commercial operations for Copiktra as it tests a newly acquired pipeline asset

Based on an early peek at clinical data, an investor syndicate is endorsing Verastem’s strategic realignment behind a pipeline combo in a targeted cancer indication. The group is pouring $100 million into the company at a double-digit premium as the biotech pares expenses.

Verastem Oncology Inc. (NASDAQ:VSTM) has identified as a key

Read the full 514 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE